Adicet Bio Inc
adicetbio.comAdicet Bio Inc (NASDAQ: ACET) is a clinical-stage biopharmaceutical company developing allogeneic gamma delta CAR-T cell therapies for cancer and autoimmune diseases. The company generates no product revenue, funding operations through capital raises while spending on research and development. As of the 10-K filed March 12, 2026, Adicet's lead candidate is prula-cel, a gamma delta CAR-T therapy in Phase 1 clinical trials for B cell-mediated autoimmune diseases including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM), and stiff person syndrome (SPS). A second pipeline candidate, ADI-212, targets PSMA. Net cash used in operating activities was $92.4 million for the year ended December 31, 2024. CEO is Nick Harvey; CFO is Nick Harvey as well per the filing signature block, with Jeffrey Chodakewitz listed as a director. Shanghai Adicet became a wholly owned subsidiary of Adicet Therapeutics following completion of registration in August 2025.
Products & Services
Prula-cel: allogeneic gamma delta CAR-T cell therapy in Phase 1 trials for autoimmune diseases (LN, SLE, SSc, AAV, IIM, SPS); FDA Fast Track Designation granted June 2024. ADI-212: next-generation gene-edited and armored CAR-T candidate targeting PSMA, with IND submission planned.
Revenue Model
No product revenue as of the filing. The company is pre-commercial, with no products approved for sale. Operations are funded through capital markets. R&D expenses include employee costs, CDMO and CRO agreements, lab materials, and facility costs.
Customers & Markets
No commercial customers. Target patient population includes individuals with B cell-mediated autoimmune diseases. Estimated prevalence of greater than 1.7 million patients in the U.S., EU5, China, and Japan across SLE (including LN), SSc, IIM, and SPS, per the FY2025 10-K filing.
Geographic Exposure
Operations in the United States and China. Shanghai Adicet became a wholly owned subsidiary of Adicet Therapeutics following regulatory registration completion in August 2025. Target markets cited as U.S., EU5, China, and Japan.
Financial Snapshot
Loading...
